Few people with peanut allergy tolerate peanut after stopping oral immunotherapy

Allergy to peanut, which is often severe, is one of the most common food allergies. Although previous studies have shown that peanut oral immunotherapy (OIT) — ingesting small, controlled amounts of peanut protein —can desensitize adults and children and prevent life-threatening allergic reactions, the optimal duration and dose is unknown.

Few people with peanut allergy tolerate peanut after stopping oral immunotherapy. Photo: Sketch/Unsplash

In a study that followed participants after OIT successfully desensitized them to peanut, discontinuing OIT or continuing OIT at a reduced dose led to a decline in its protective effects.

The study also found that several blood tests administered before OIT could predict the success of therapy. The Phase 2 study may inform who may benefit from peanut OIT and what changes in this experimental treatment should be implemented.

Investigators at Stanford University enrolled 120 people aged 7 to 55 with diagnosed peanut allergy in the Peanut Oral Immunotherapy Study: Safety Efficacy and Discovery, or POISED. While otherwise avoiding peanut throughout the trial, 95 participants received gradually increasing daily doses of peanut protein up to 4 grams, and 25 participants received daily placebo oat flour OIT.

After 24 months, participants were given gradually increasing amounts of peanut in a controlled environment, to assess their tolerance. Of those participants who received peanut OIT, 83% passed the peanut challenge without an allergic reaction, while only 4% on placebo OIT did so.

Those on OIT who passed the challenge were then randomized to receive either placebo OIT or were switched to a 300-mg daily dose of peanut protein.

One year later, more participants on 300-mg peanut OIT (37%) passed the challenge than those on placebo OIT (13%), confirming insights from smaller trials that desensitization is maintained in only a minority of participants after OIT is discontinued or reduced.

Participants who passed food challenges also had lower initial levels of allergic antibodies to peanut protein and other indicators of allergic activity in the blood. Future research will focus on identifying optimal OIT regimens that maintain protection after therapy and will allow for regular food consumption without allergic symptoms. (National Institutes of Health)

YOU MAY ALSO LIKE

Disrupting the gut microbiome may affect some immune responses to flu vaccination

Researchers from Stanford University found that oral antibiotics, which can kill gut microorganisms, can alter the human immune response to seasonal influenza vaccination.

Nanoparticles used to transport anti-cancer agent to cells

Scientists from the University of Cambridge have developed a platform that uses nanoparticles known as metal-organic frameworks to deliver a promising anti-cancer agent to cells.

The brain may actively forget during dream sleep

Rapid eye movement, or REM, sleep is a fascinating period when most of our dreams are made. Now, in a study of mice, a team of Japanese and U.S. researchers show that it may also be a time when the brain actively forgets.

Zika virus found to harm adults’ memory and motor system

A study by scientists at the Federal University of Rio de Janeiro (UFRJ) found that the Zika virus, in addition to replicating in the brain of adults, also damages the memory and the motor system.

Molecule in Immune System Able to Trigger 'Suicide' of Cancerous Tumors

Researchers discovered a molecule in the immune system that could naturally kill cancer cells.

First-time pregnancy complications linked to increased risk of hypertension later in life

Women who experience complications such as preterm births and preeclampsia during their first pregnancy are nearly twice more likely than women without complications to develop high blood pressure later in life — some as quickly as three years later.